Skip to main content
Nicox S.A. logo

Nicox S.A. — Investor Relations & Filings

Ticker · COX ISIN · FR0013018124 LEI · 969500EZGEO9W4JXR353 PA Professional, scientific and technical activities
Open in API
Filings indexed 799 across all filing types
Latest filing 2023-01-09 Capital/Financing Update
Country FR France
Listing PA COX

About Nicox S.A.

https://www.nicox.com/

Nicox S.A. is an international ophthalmology company focused on the research and development of innovative therapeutic solutions to maintain vision and improve ocular health. The company's lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost analog in late-stage clinical development for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox's pipeline is based on its proprietary NO-donating research platform. The company has also developed two approved ophthalmic products: VYZULTA® (latanoprostene bunod ophthalmic solution), licensed exclusively to Bausch + Lomb, and ZERVIATE® (cetirizine ophthalmic solution), licensed to various partners for commercialization.

Recent filings

Filing Released Lang Actions
Nicox Announces Proposed Move to Euronext Growth Paris
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the company's intention to transfer its listing from the Euronext Paris regulated market to Euronext Growth Paris. Crucially, it also announces that an 'ordinary shareholder meeting' has been convened for February 14, 2023, to vote on this proposed transfer. The text details the documents related to this meeting (proxy voting form, etc.) and the process for shareholders to vote. This content directly relates to the preparation for and subject matter of a general meeting, specifically concerning corporate governance and shareholder decisions. The most fitting category is 'AGM Information' (AGM-R) because it concerns the convening and materials for a shareholder meeting, even though the primary topic is a listing change. It is not a DEF 14A (Remuneration) or DVA (Voting Results), but rather the announcement leading up to the vote on a major corporate action.
2023-01-09 English
Nicox : Projet de transfert de la cotation des actions vers Euronext Growth Paris
Delisting Announcement Classification · 99% confidence The document is a press release ('Communiqué de presse') dated January 9, 2023, announcing two main items: 1) The intention to transfer the listing of Nicox shares from the regulated market Euronext Paris to Euronext Growth Paris. 2) The convening of an Ordinary General Meeting (AGM) on February 14, 2023, to vote on this transfer project. The text details the consequences of the transfer regarding periodic information, permanent information, and shareholder protection, and provides a timeline contingent on the AGM vote. Since the primary purpose is to announce the upcoming shareholder vote regarding a significant corporate action (listing transfer) and it explicitly mentions convening the 'Assemblée générale ordinaire' (AGM), it strongly relates to shareholder meeting procedures and proposals. While it announces the AGM, the core subject matter is the proposal being voted on, which is a major corporate governance/capital structure event. However, the document is a press release announcing the meeting and the proposal, not the formal proxy materials (PSI) or the results (DVA). Given the focus on convening the AGM and the nature of the proposal, it is most closely related to the general context of shareholder meetings. Since the document is a press release announcing the meeting and the proposal, and not the formal proxy statement or the results, it fits best as a general announcement related to corporate governance or a regulatory filing. The most specific fit among the options that covers the announcement of a general meeting and related corporate actions is often related to governance or the meeting itself. Since it is a press release announcing the AGM and the proposal, and the AGM materials themselves are mentioned as being made available later, it is not PSI or DVA yet. It is an announcement of corporate action and a meeting. Given the options, 'AGM-R' (AGM Information) is plausible as it concerns the AGM, but 'RPA' (Report Publication Announcement) is often used for press releases announcing corporate actions or reports. However, the content is heavily focused on the AGM itself. Let's re-evaluate based on the content: it's a press release announcing the date and agenda for the AGM. This is often categorized under AGM-R if it contains presentation-like material, or RPA if it's just the announcement. Since it details the agenda and the proposal to be voted on, it is highly relevant to the AGM. If the document were the actual proxy materials, it would be PSI. As a press release announcing the meeting, AGM-R is a strong candidate, but RPA is also possible if we treat it purely as a 'publication announcement'. Given the explicit focus on convening the AGM and the details provided about the meeting logistics and agenda, AGM-R is the most contextually relevant classification for materials related to the AGM, even if it's the pre-announcement press release. I will classify it as AGM-R as it is centered around the upcoming AGM.
2023-01-09 French
Nicox : Bilan semestriel du contrat de liquidité avec Kepler Cheuvreux
Regulatory Filings Classification · 99% confidence The document is titled "Communiqué de presse" (Press Release) and provides a "Bilan semestriel du contrat de liquidité avec Kepler Cheuvreux" (Semi-annual balance sheet of the liquidity contract with Kepler Cheuvreux) dated January 6, 2023, detailing activity up to December 31, 2022. This document reports on the execution of a liquidity contract (share trading activities managed by a third party) over a six-month period. This type of disclosure, which details share transactions by the company or its designated agent for market stabilization/liquidity purposes, falls under the category of reporting on the company's own shares transactions. The most specific category is 'Transaction in Own Shares' (POS). It is not a general earnings release (ER), nor a comprehensive interim report (IR), but a specific disclosure about share repurchase/issuance activities managed under a contract.
2023-01-06 French
Nicox: Half-year liquidity contract statement with Kepler Cheuvreux
Regulatory Filings Classification · 99% confidence The document is titled "Press Release" and specifically details the "Half-year liquidity contract statement with Kepler Cheuvreux" for Nicox, dated January 6, 2023, covering activity up to December 31, 2022. It reports on the status of a liquidity contract, including share counts, cash balances, and transaction volumes (buy side vs. sell side) over a semester, comparing the current period (ending Dec 31, 2022) with the previous half-year (ending June 30, 2022). This type of regular, periodic disclosure regarding market making or liquidity provision activities, often mandated by regulatory bodies like the AMF (mentioned in the text), does not fit neatly into standard financial reports (10-K, IR, ER) or corporate actions (DIV, SHA). It is a specific regulatory disclosure concerning market operations. Since it is a specific regulatory announcement that doesn't match the other defined categories (like DIRS for insider trading or MRQ for major shareholding changes), the most appropriate classification is the general regulatory fallback category, RNS (Regulatory Filings).
2023-01-06 English
Nombre de droits de vote au 31 décembre 2022
Share Issue/Capital Change Classification · 99% confidence The document is titled "PUBLICATION MENSUELLE DU NOMBRE D'ACTIONS COMPOSANT LE CAPITAL ET DU NOMBRE TOTAL DE DROITS DE VOTE" (Monthly publication of the number of shares comprising the capital and the total number of voting rights), dated January 3, 2023, referencing data as of December 31, 2022. It explicitly cites French regulatory articles (Code de Commerce and AMF regulations) for this disclosure. This type of mandatory monthly disclosure regarding the total share capital and voting rights does not fit neatly into the primary categories like 10-K, ER, or IR. It is a specific regulatory disclosure concerning share structure. Since it is a specific, recurring regulatory announcement that isn't covered by a more precise code (like DIRS or DIV), the most appropriate general category is Regulatory Filings (RNS), as it serves as a mandatory regulatory update.
2023-01-03 French
Number of voting rights as of December 31, 2022
Share Issue/Capital Change Classification · 99% confidence The document is a short, formal notice published monthly (as indicated by the date 'January 3, 2023' and the title referencing 'MONTHLY PUBLICATION'). It explicitly states the 'Total number of shares composing the share capital' and 'Total number of voting rights' as required by French commercial code (Code de Commerce and AMF regulations). This type of periodic disclosure regarding share capital and voting rights does not fit neatly into the primary financial reports (10-K, IR) or specific corporate actions (DIV, SHA). Since it is a mandatory regulatory disclosure that doesn't match a more specific category like Director's Dealing (DIRS) or Major Shareholding (MRQ), it falls best under the general 'Regulatory Filings' category, which serves as a fallback for miscellaneous regulatory announcements.
2023-01-03 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.